DTCs/CTCs in breast cancer: Five decades later

Recent Results in Cancer Research

Volumn 195, Issue , 2012, Pages 217-225

  Alsamarai, Susan ^a   Abu Khalaf, Maysa M ^a   Harris, Lyndsay N ^b  

^a YALE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CELL ASSAY; CELL FUNCTION; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EARLY CANCER; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY;

BONE MARROW; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM MICROMETASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860579853     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-28160-0_20     Document Type: Article

References (37)

1. Engell HC (1955) Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation. Acta Chir Scand Suppl 201:1-70
2. Berger U, Bettelheim R, Mansi J (1988) The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 90(1):1-6
3. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, Coombes RC (1991) Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 27(12):1552-1555
4. Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F, Barletta L, Menard S, Colnaghi MI (1990) Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer 26(8):865-867
5. Molino A, Pelosi G, MIHCioli R, Turazza M, Nortilli R, Pavanel F, Cetto GL (1999) Bone marrow micrometastases in breast cancer patients. Breast Cancer Res Treat 58(2):123-130 (Pubitemid 30032483)
6. Schlimok G, Lindemann F, Holzman K, et al (1992) Prognostic significance of disseminated tumor cells detected in bone marrow of patients with breast and colorectal cancer: a multivariate analysis. Proc Am Soc Clin Oncol 11(102):abs 232
7. Braun S, Pantel K,Muller, JanniW, Hepp F, Kentenich CR, Gastroph S,Wischnik A, Dimpfl T, KindermannG, RiethmullerG, SchlimokG(2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342(8):525-533 (Pubitemid 30117892)
8. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781-791 (Pubitemid 39095313)
9. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LWWM (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14):4218-4224
10. Bidard FC, Mathiot C, Degeorges A et al (2010) Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 21:1765-1771
11. Giordano A, Giuliano M, Hsu L, et al. (2010) Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol 28:7s, (Suppl, abstr 1000)
12. Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN (2009) Circulating tumor cells in HER-2positive metastatic breast cancer patients treatedwith trastuzumab and chemotherapy. Int J Biol Markers 24(1):1-10
13. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M (2010) Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J 16(3):327-330
14. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K (2010)HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 124(2):403-412
15. You F, Roberts LA, Kang SP, Nunes RA, Dias C, Iglehart JD, Solomon NA, Friedman PN, Harris LN (2008) Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. Hematol Oncol 28(1):2
16. Mego M, De Giorgi U, Dawood S, Wang X , Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M (2011) Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer 129(2):417-423
17. Mego M, Mani SA, Lee B-N, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM (2012) Expression of epithelialmesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer 130(4):808-816
18. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11(4):R46
19. GradiloneA,RaimondiC,NicolazzoC, PetraccaA,GandiniO,VincenziB,NasoG, AglianòAM, Cortesi E, Gazzaniga P (2011) Circulating tumor cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med 15(5):1066-1070
20. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P (2011) Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 130(2):449-455
21. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235-1239
22. Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192(3):373-382
23. Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK et al (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107:18392-18397. doi:10.1073/pnas. 1012539107
24. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, Bischoff FZ, Pircher TJ (2011) Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011:252361, [Epub 2011 Apr 19]
25. Pierga JY, Bidard FC, Mathiot C et al (2008) Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14:7004-7010
26. Riethdorf S, Fritsche H, Muller V et al (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 13:920-928 (Pubitemid 46340368)
27. Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16(9):2634-2645
28. Braun S, PantelK, Müller P, Janni W, Hepp F, Kentenich C, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G (2000) Cytokeratin positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:8
29. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin Cancer Res 17(9):2967-2976
30. Krishnamurthy S, Cristofanilli M, Singh B et al (2010) Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116(14):3330-3337
31. Slade MJ, Payne R, Riethdorf S, Ward B, Zaidi SA, Stebbing J, Palmieri C, Sinnett HD, Kulinskaya E, Pitfield T, McCormack RT, Pantel K, Coombes RC (2009) Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer 100:160-166
32. Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, Kasimir-Bauer S (2009) Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 11(5):R71
33. Rack BK et al (2010) Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. J Clin Oncol 28(15):1003
34. Bidard FC, Mathiot C, Delaloge S et al (2009) Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21(4):729-733
35. Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D (2011) Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res 13(3):R60
36. Xenidis N, Ignatiadis M, Apostolaki S et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27(13):2177-2184
37. Sandri MT, Zorzino L, Cassatella MC et al (2010) Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 17(6): 1539-1545